{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:02:13Z","timestamp":1790301733693,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T00:00:00Z","timestamp":1361232000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s00702-013-0992-2","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T03:34:37Z","timestamp":1361244877000},"page":"903-910","source":"Crossref","is-referenced-by-count":25,"title":["Interaction of selegiline-loaded PLGA-b-PEG nanoparticles with beta-amyloid fibrils"],"prefix":"10.1007","volume":"120","author":[{"given":"Ipek","family":"Baysal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiye","family":"Yabanoglu-Ciftci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeliz","family":"Tunc-Sarisozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezban","family":"Ulubayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulberk","family":"Ucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,19]]},"reference":[{"key":"992_CR1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s002280050702","volume":"55","author":"I Alafuzoff","year":"2000","unstructured":"Alafuzoff I, Helisalmi S, Heinonen EH, Reinikainen K, Hallikainen M, Soininen H, Koivisto K (2000) Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer\u2019s disease. Eur J Clin Pharmacol 55:815\u2013819","journal-title":"Eur J Clin Pharmacol"},{"key":"992_CR2","first-page":"146","volume":"64","author":"A Alzheimer","year":"1907","unstructured":"Alzheimer A (1907) Uber eine eijenartige Erkrankung der Hirnride. Allg Z Psychiatr 64:146\u2013148","journal-title":"Allg Z Psychiatr"},{"issue":"2","key":"992_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1043-6618(02)00090-7","volume":"46","author":"C Antoniadesa","year":"2002","unstructured":"Antoniadesa C, Carageorgioub H, Tsakirisa S (2002) Effects of (\u2212)deprenyl (selegiline) on acetylcholinesterase and Na+, K+ -ATPase activities in adult rat whole brain. Pharmacol Res 46(2):165\u2013169","journal-title":"Pharmacol Res"},{"issue":"5","key":"992_CR4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i5.20","volume":"21","author":"I Bala","year":"2004","unstructured":"Bala I, Hariharan S, Kumar MN (2004) PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 21(5):387\u2013422","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"992_CR5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s000180300002","volume":"60","author":"G Barratt","year":"2003","unstructured":"Barratt G (2003) Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci 60:21\u201337","journal-title":"Cell Mol Life Sci"},{"key":"992_CR6","first-page":"CD000442","volume":"1","author":"J Birks","year":"2003","unstructured":"Birks J, Flicker L (2003) Selegiline for Alzheimer\u2019s disease. Cochrane Database syst Rev 1:CD000442","journal-title":"Cochrane Database syst Rev"},{"issue":"2001","key":"992_CR7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1023\/A:1010931127745","volume":"18","author":"P Calvo","year":"2001","unstructured":"Calvo P, Gouritin B, Chacun H, Desmaele D, D\u2019Angelo J, Noel JP, Georgin D, Fattal E, Andreux JP, Couvreur P (2001) Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 18(2001):1157\u20131166","journal-title":"Pharm Res"},{"issue":"12","key":"992_CR8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0166-2236(02)02263-4","volume":"25","author":"F Checler","year":"2002","unstructured":"Checler F, Vincent B (2002) Alzheimer\u2019s and prion diseases: distinct pathologies, common proteolytic denominators. Trends Neurosci 25(12):616\u2013620","journal-title":"Trends Neurosci"},{"key":"992_CR9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.copbio.2011.05.507","volume":"22","author":"R Duncan","year":"2011","unstructured":"Duncan R (2011) Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol 22:492\u2013501","journal-title":"Curr Opin Biotechnol"},{"issue":"4\u20135","key":"992_CR10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.neuint.2007.09.006","volume":"52","author":"SS Durairajan","year":"2008","unstructured":"Durairajan SS, Yuan Q, Xie L, Chan WS, Kum WF, Koo I, Liu C, Song Y, Huang JD, Klein WL, Li M (2008) Salvianolic acid B inhibits A\u03b2 fibril formation and disaggregates preformed fibrils and protects against A\u03b2-induced cytotoxicty. Neurochem Int 52(4\u20135):741\u2013750","journal-title":"Neurochem Int"},{"key":"992_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1353-8020(99)00043-7","volume":"6","author":"P Foley","year":"2000","unstructured":"Foley P, Gerlach M, Youdim MBH, Riederer P (2000) MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders. Parkinsonism Relat Disord 6:25\u201347","journal-title":"Parkinsonism Relat Disord"},{"key":"992_CR13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1359-0286(02)00117-1","volume":"6","author":"ML Hans","year":"2002","unstructured":"Hans ML, Lowman AM (2002) Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 6:319\u2013327","journal-title":"Curr Opin Solid State Mater Sci"},{"key":"992_CR14","doi-asserted-by":"crossref","first-page":"15514","DOI":"10.1021\/bi991161m","volume":"38","author":"K Hasegawa","year":"1999","unstructured":"Hasegawa K, Yamaguchi I, Omata S, Gejyo F, Naiki H (1999) Interaction between A beta(1\u201342) and A beta(1\u201340) in Alzheimer\u2019s beta-amyloid fibril formation in vitro. Biochemistry 38:15514\u201315521","journal-title":"Biochemistry"},{"key":"992_CR15","first-page":"213","volume":"28","author":"S Hiller-Sturmh\u00f6fel","year":"2004","unstructured":"Hiller-Sturmh\u00f6fel S, Swartzwelder S (2004) Alcohol\u2019s effects on the adolescent brain\u2014what can be learned from animal models. Alcohol Res Health 28:213\u2013221","journal-title":"Alcohol Res Health"},{"issue":"6","key":"992_CR16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jbiosc.2009.11.010","volume":"109","author":"VT Huong","year":"2010","unstructured":"Huong VT, Shimanouchi T, Shimauchi N, Yagi H, Umakoshi H, Goto Y, Kuboi R (2010) Catechol derivatives inhibit the fibril formation of amyloid-beta peptides. J Biosci Bioeng 109(6):629\u2013634","journal-title":"J Biosci Bioeng"},{"key":"992_CR17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0773.1998.tb01399.x","volume":"82","author":"J Knoll","year":"1998","unstructured":"Knoll J (1998) (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol 82:57\u201366","journal-title":"Pharmacol Toxicol"},{"key":"992_CR18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson N, Zetterberg H, Hansson O (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. J Am Med Assoc 302:385\u2013393","journal-title":"J Am Med Assoc"},{"issue":"5","key":"992_CR19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjp.0707130","volume":"150","author":"C Medina","year":"2007","unstructured":"Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW (2007) Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 150(5):552\u2013558","journal-title":"Br J Pharmacol"},{"key":"992_CR20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0928-0987(02)00251-8","volume":"18","author":"E Merisko-Liversidge","year":"2002","unstructured":"Merisko-Liversidge E, Liversidge GG, Cooper ER (2002) Nanosizing: a formulation approach for poorly water-soluble compounds. Eur J Pharm Sci 18:113\u2013120","journal-title":"Eur J Pharm Sci"},{"key":"992_CR21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1023\/A:1019842024814","volume":"19","author":"JC Olivier","year":"2002","unstructured":"Olivier JC, Huertas R, Lee HJ, Calon FWM (2002) Synthesis of pegylated immunonanoparticles. Pharm Res 19:1137\u20131143","journal-title":"Pharm Res"},{"issue":"1","key":"992_CR22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/brain\/92.1.147","volume":"92","author":"M Olson","year":"1969","unstructured":"Olson M, Shaw CM (1969) Presenile dementia and Alzheimer\u2019s disease in mongolism. Brain 92(1):147\u2013156","journal-title":"Brain"},{"key":"992_CR23","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1046\/j.1471-4159.2002.00904.x","volume":"81","author":"K Ono","year":"2002","unstructured":"Ono K, Hasegawa K, Yoshiike Y, Takashima A, Yamada M, Naiki H (2002) Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer\u2019s beta-amyloid fibrils in vitro. J Neurochem 81:434\u2013440","journal-title":"J Neurochem"},{"issue":"6","key":"992_CR24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/jnr.20025","volume":"75","author":"K Ono","year":"2004","unstructured":"Ono K, Hasegawa K, Naiki H, Yamada M (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer\u2019s \u03b2-amyloid fibrils in vitro. J Neurosci Res 75(6):742\u2013750","journal-title":"J Neurosci Res"},{"key":"992_CR25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuint.2005.11.001","volume":"48","author":"K Ono","year":"2006","unstructured":"Ono K, Hasegawa K, Naiki H, Yamada H (2006) Anti-parkinsonian agents have anti-amyloidogenic activity for Alzheimer\u2019s \u03b2-amyloid fibrils in vitro. Neurochem Int 48:275\u2013285","journal-title":"Neurochem Int"},{"key":"992_CR26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0928-0987(03)00019-8","volume":"18","author":"A Sanchez","year":"2003","unstructured":"Sanchez A, Tobio M, Gonzalez L, Fabra A, Alonso MJ (2003) Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci 18:221\u2013229","journal-title":"Eur J Pharm Sci"},{"key":"992_CR27","unstructured":"Sar\u0131 E (2011) Development of ICAM-1 directed catalase loaded polymeric nanoparticles against vascular oxidative stress"},{"key":"992_CR28","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.283.12.1615","volume":"283","author":"DJ Selkoe","year":"2000","unstructured":"Selkoe DJ (2000) The origins of Alzheimer\u2019s disease: a is for amyloid. J Am Med Assoc 283:1615\u20131617","journal-title":"J Am Med Assoc"},{"key":"992_CR29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0166-2236(98)01337-X","volume":"21","author":"MG Spillantini","year":"1998","unstructured":"Spillantini MG, Goedert M (1998) The protein pathology in neurodegenerative diseases. Trends Neurosci 21:428\u2013433","journal-title":"Trends Neurosci"},{"key":"992_CR30","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpba.2007.11.039","volume":"46","author":"PD Tzanavaras","year":"2008","unstructured":"Tzanavaras PD, Themelis DG, Zotuo A, Stratis J, Karlberg B (2008) Optimization and validation of a dissolution test for selegiline hydrochloride tablets by a novel rapid HPLC assay using a monolithic stationary phase. J Pharm Biomed Anal 46:670\u2013675","journal-title":"J Pharm Biomed Anal"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-0992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-013-0992-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-0992-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:30:23Z","timestamp":1559104223000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-013-0992-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,19]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1007\/s00702-013-0992-2","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,19]]}}}